The HDAC1 Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population engineered for disruption of the HDAC1 gene in the human A2780 ovarian carcinoma background. This loss-of-function model provides a genetically heterogeneous knockout pool suitable for studying HDAC1-dependent processes without clonal selection biases. The polyclonal format enables robust population-level analyses of HDAC1??s role in chromatin regulation and drug response, reflecting a more physiologically relevant cellular context compared to monoclonal isolates.
The A2780 cell line, derived from a patient with ovarian carcinoma, is widely employed in cancer research for proliferation, apoptosis, and drug sensitivity studies. This epithelial line retains key oncogenic signaling pathways and serves as a relevant model for high-grade serous ovarian carcinoma, particularly for investigating mechanisms of platinum resistance and HDAC inhibitor efficacy. Its well-characterized genetic landscape and reproducible growth characteristics make it an ideal platform for gene-editing applications.
HDAC1 is a class I histone deacetylase that catalyzes the removal of acetyl groups from lysine residues on histones, leading to chromatin compaction and transcriptional repression. It functions within multiprotein complexes containing corepressors such as SIN3A, NCOR1, and MTA2. HDAC1 activity is regulated by upstream transcription factors including MYC and E2F1, and it directly represses tumor suppressor genes like CDKN1A (p21) and BAX. Through these interactions, HDAC1 influences cell cycle progression, apoptosis, and differentiation. Additionally, HDAC1 participates in the Notch pathway via NOTCH1 and RBPJ, the Wnt/??-catenin axis through CTNNB1 and TCF7L2, and TGF-?? signaling involving SMAD2 and SMAD3.
In A2780 cells, disruption of HDAC1 leads to hyperacetylation of histones and chromatin relaxation, causing derepression of key tumor suppressor genes. Notably, upregulation of CDKN1A and BAX promotes cell cycle arrest and apoptosis, respectively, while altered expression of MYC and TP53 may affect proliferation and survival. This hyperacetylated state can also impact the cellular response to HDAC inhibitors and chemotherapeutic agents, providing a valuable tool to dissect drug resistance mechanisms. The polyclonal nature of the knockout population allows assessment of functional consequences at the population level, mirroring tumor heterogeneity.
This HDAC1 knockout model is suitable for a wide range of applications, including chromatin immunoprecipitation (ChIP) to examine histone acetylation dynamics, transcriptomic profiling via RNA-seq to identify HDAC1-regulated gene networks, and functional assays such as flow cytometry for cell cycle and apoptosis analysis. Researchers can utilize Western blotting and RT-qPCR to validate target gene expression changes and employ co-immunoprecipitation to explore HDAC1 complex composition. Additionally, this model facilitates drug sensitivity screens and migration/invasion assays. For further technical information or custom inquiries, please contact Ascent Research.
